Peptide Cycle Length Guide: How Long Should You Run Each Compound?

Why Peptide Cycle Length Matters

Many peptides are used in defined cycles — active use followed by rest. Reasons vary by compound:

• Receptor desensitization: Some peptides lose effectiveness as receptors downregulate
• Safety margins: Without long-term human data, cycling limits cumulative exposure
• Physiological reset: Some compounds work best with intermittent stimulation

Not all peptides need cycling. FDA-approved semaglutide and tirzepatide are designed for continuous use. For general dosing principles, see our Peptide Dosage Guide.

Cycle Length by Compound

Compound	Cycle	Off Period	Cycling Needed?	Reason
BPC-157	4-8 weeks	4+ weeks	Yes	Limited long-term data; angiogenic
TB-500	4-8 weeks	4+ weeks	Yes	Same as BPC-157
Ipamorelin	8-12 weeks	4-8 weeks	Recommended	Ghrelin receptor desensitization
CJC-1295	8-12 weeks	4-8 weeks	Recommended	GHRH receptor tolerance
Sermorelin	3-6 months	1-3 months	Debated	Clinical protocols often continuous
GHK-Cu (injectable)	4-8 weeks	4 weeks	Yes	Limited injectable data
GHK-Cu (topical)	Continuous	N/A	No	Low systemic exposure
Semaglutide	Continuous	N/A	No	FDA-approved long-term
Tirzepatide	Continuous	N/A	No	FDA-approved long-term
Tesamorelin	Continuous	N/A	No	FDA-approved; benefits reverse
Semax	2-4 weeks	2-4 weeks	Yes	Russian clinical guidelines
Selank	2-4 weeks	2-4 weeks	Yes	Clinical cycling protocols
Dihexa	2-4 weeks	4-8 weeks	Yes	Very limited data; HGF concerns
Epitalon	10-20 days	4-6 months	Yes	Khavinson protocol
PT-141	As needed	N/A	On-demand	Acute use, not chronic

Healing Peptides: BPC-157 and TB-500

• Duration: 4-8 weeks (6 most common)
• Off period: 4+ weeks
• Rationale: Both promote angiogenesis; sustained stimulation has theoretical concerns. Short targeted cycles limit exposure
• Repeat: Second cycle after off period if healing needs to continue

See the BPC-157 + TB-500 Stack Protocol for the complete healing protocol.

GH Secretagogues

GH secretagogues face receptor desensitization — the ghrelin receptor (GHS-R1a) downregulates with sustained stimulation.^[2]

• Standard cycle: 8-12 weeks
• Off period: 4-8 weeks for receptor resensitization
• Monitor IGF-1: Best objective measure. If levels plateau or decline, desensitization has occurred
• Use minimum effective dose to extend useful cycle length

See the GH Optimization Stack for CJC-1295 + Ipamorelin protocol.

GLP-1 Agonists: Continuous Use

GLP-1 medications are the exception:^[1]

• STEP 1 extension showed approximately two-thirds weight regain within 12 months of stopping semaglutide
• No receptor desensitization at therapeutic doses
• Cardiovascular benefits require ongoing treatment

See our Semaglutide vs Tirzepatide comparison.

Nootropic Peptides: Short Cycles

• Semax/Selank: 2-4 weeks on, 2-4 weeks off (Russian clinical guidelines)
• Dihexa: 2-4 weeks on, 4-8 weeks off (limited data; HGF concerns)
• Cerebrolysin: 10-20 day courses, 2-4x per year (European clinical protocol)
• Epitalon: 10-20 days on, 4-6 months off (Khavinson protocol)^[3]

Decision Framework

1. FDA-approved for your use case? Follow the approved protocol (usually continuous)
2. Established clinical cycling protocol? Follow it (semax, selank, cerebrolysin, epitalon)
3. Defined purpose with clear endpoint? Use until goal achieved or standard duration
4. Works through receptor agonism? Factor in desensitization; plan finite cycle with monitoring
5. When in doubt, shorter is safer

For compound-specific protocols, visit individual pages in our Compound Database.